Thanks for that reference -- interesting interview of what seemed to be an unbiased and knowledgeable guy. Couple of weak spots -- such as his reaction to the patients being under 25. Dr. Grupp reacted negatively to this fact (which he was not aware of ahead of time), but he didn't really understand that the company was only providing this as additional information. in no way did JUNO suggest that the problem could be avoided if the patients were older.
Agree with all of your points. I would add regarding point 3 that there aren't even any lawsuits -- these are "investigations" -- meaning these are young lawyers (check them on LinkedIn) trolling for clients and information. There is no legal case here. What -- the company didn't disclose that sick people might die? So if there is a lawsuit, it will be dismissed by the judge. (Federal judges know this game and have little patience with this kind of waste of resources.)
Sorry -- the CELG/JUNO deal wasn't that recent -- signed in June of last year.
Bunch of co-development and co-promotional rights -- blah blah blah. CELG did fork over $1B and got about 9M shares of JUNO -- so a $10 per share drop is a $100M hit to the balance sheet. This alone is not that big of a deal IMO.
I am pretty sure that CELG is down due to the termination of the JUNO JCAR015 Phase II ROCKET Trial. Two patients dies due to a "preconditioning" in the protocol -- and the company has requested permission to modify the protocol.
CELG recently announced an agreement with JUNO regarding a participation -- although I am not sure of the details. (No doubt there will be a significant delay at a minimum.) Likely it is a question of shoot first and ask questions later. Can't blame people for that behavior given the way the biotechs have been treated lately.